Withdrawal of Approval of a New Animal Drug Application; Bacitracin Zinc, 49282 [E7-16985]
Download as PDF
<![CDATA[
49282
Federal Register / Vol. 72, No. 166 / Tuesday, August 28, 2007 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0324]
Withdrawal of Approval of a New
Animal Drug Application; Bacitracin
Zinc
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is withdrawing
approval of a new animal drug
application (NADA) for a bacitracin zinc
Type A medicated article. In a final rule
published elsewhere in this issue of the
Federal Register, FDA is amending the
animal drug regulations to remove
portions reflecting approval of this
NADA.
FOR FURTHER INFORMATION CONTACT:
Pamela K. Esposito, Center for
Veterinary Medicine (HFV–212), Food
and Drug Administration, 7519 Standish
Pl., Rockville, MD 20855, 301–827–
7818; e-mail:
pamela.esposito@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pennfield
Oil Co., 14040 Industrial Rd., Omaha,
NE 68144, has requested that FDA
withdraw approval of NADA 128–550
for ANCHOR Zinc Bacitracin Type A
medicated article because the product is
not manufactured or marketed.
Therefore, under authority delegated
to the Commissioner of Food and Drugs
and redelegated to the Center for
Veterinary Medicine, and in accordance
with § 514.115 Withdrawal of approval
of applications (21 CFR 514.115), notice
is given that approval of NADA 128–
550, and all supplements and
amendments thereto, are hereby
withdrawn, effective August 28, 2007.
In a final rule published elsewhere in
this issue of the Federal Register, FDA
is amending the animal drug regulations
to reflect the withdrawal of approval of
this NADA.
Dated: August 20, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7–16985 Filed 8–27–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Pretesting of NIAID’s HIV
Vaccine Research Communications
Messages
SUMMARY: In compliance with the
requirement of section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Institute of Allergy and
Infectious Diseases (NIAID), the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: Pretesting
of NIAID’s HIV Vaccine Research
Estimated
number of
respondents
Type of respondents
Communications Messages. Type of
Information Collection Request: NEW.
Need and Use of Information Collection:
This is a request for clearance to pretest
messages, materials and program
activities produced for the NIAID HIV
Vaccine Research Education Initiative
(NHVREI). The primary objectives of the
pretests are to (1) Assess audience
knowledge, attitudes, behaviors and
other characteristics for the planning/
development of health messages,
education products, communication
strategies, and public information
programs; and (2) pretest these health
messages, products, strategies, and
program components while they are in
developmental form to assess audience
comprehension, reactions, and
perceptions. The information obtained
from audience research and pretesting
results in more effective messages,
materials, and programmatic strategies.
By maximizing the effectiveness of these
messages and strategies for reaching
targeted audiences, the frequency with
which publications, products, and
programs need to be modified is
reduced. Frequency of Response: On
occasion. Affected Public: Individuals.
Type of Respondents: Adults at risk for
HIV/AIDS, particularly those who are
Black/African-American, Hispanic/
Latino, or men who have sex with men;
healthcare providers; representatives of
organizations disseminating HIV-related
messages or materials. The annual
reporting burden is shown in the table
below. There are no Capital Costs to
report. There are no Operating or
Maintenance Costs to report.
Estimated
number of
responses per
respondent
Average
burden hours
per response
3,374
50
75
1
1
1
.3422
.75
.50
Total ......................................................................................................
pwalker on PROD1PC71 with NOTICES
At-risk Adults ................................................................................................
Healthcare providers ....................................................................................
Organization Gatekeepers ...........................................................................
3,499
........................
..........................
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
VerDate Aug<31>2005
19:52 Aug 27, 2007
Jkt 211001
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To request
more information on the proposed
project or to obtain a copy of the data
collection plans and instruments,
contact Katharine Kripke, Assistant
FOR FURTHER INFORMATION:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Estimated total
annual burden
hours requested
1155
37.5
37.5
1230
Director, Vaccine Research Program,
Division of AIDS, NIAID, NIH, 6700B
Rockledge Dr., Bethesda, MD 20892–
7628, or call non-toll-free number 301–
402–0846, or e-mail your request,
including your address to
kripkek@niaid.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 72, Number 166 (Tuesday, August 28, 2007)]
[Notices]
[Page 49282]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16985]
[[Page 49282]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0324]
Withdrawal of Approval of a New Animal Drug Application;
Bacitracin Zinc
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval
of a new animal drug application (NADA) for a bacitracin zinc Type A
medicated article. In a final rule published elsewhere in this issue of
the Federal Register, FDA is amending the animal drug regulations to
remove portions reflecting approval of this NADA.
FOR FURTHER INFORMATION CONTACT: Pamela K. Esposito, Center for
Veterinary Medicine (HFV-212), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855, 301-827-7818; e-mail:
pamela.esposito@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pennfield Oil Co., 14040 Industrial Rd.,
Omaha, NE 68144, has requested that FDA withdraw approval of NADA 128-
550 for ANCHOR Zinc Bacitracin Type A medicated article because the
product is not manufactured or marketed.
Therefore, under authority delegated to the Commissioner of Food
and Drugs and redelegated to the Center for Veterinary Medicine, and in
accordance with Sec. 514.115 Withdrawal of approval of applications
(21 CFR 514.115), notice is given that approval of NADA 128-550, and
all supplements and amendments thereto, are hereby withdrawn, effective
August 28, 2007.
In a final rule published elsewhere in this issue of the Federal
Register, FDA is amending the animal drug regulations to reflect the
withdrawal of approval of this NADA.
Dated: August 20, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7-16985 Filed 8-27-07; 8:45 am]
BILLING CODE 4160-01-S
